Farmaco anti obesità cura gli spermatozoi e migliora la funzione sessuale maschile

Farmaco anti obesità cura gli spermatozoi e migliora la funzione sessuale maschile: lo studio dei ricercatori degli atenei di Catania e Catanzaro è stato pubblicato sulla Rivista Internazionale “Journal of Clinical Medicine".

 

Un importante studio clinico è stato pubblicato sulla rivista Internazionale “Journal of Clinical Medicine” dal titolo "Sexual and Reproductive Outcomes in Obese Fertile Men with Functional Hypogonadism after Treatment with Liraglutide: Preliminary Results" che dimostra per la prima volta come un farmaco impiegato per la cura dell'obesità (Liraglutide 3.0 mg) si rivela efficace nel migliorare la qualità spermatica e la funzione erettile negli uomini obesi. La ricerca è stata condotta dai ricercatori Sandro La Vignera, Rosita A. Condorelli, Aldo E. Calogero e Rossella Cannarella del Dipartimento di Medicina clinica e sperimentale dell’Università di Catania e Antonio Aversa del Dipartimento di Medicina clinica e sperimental dell’Università Magna Graecia di Catanzaro.

Epidemiology and semeiotics of endocrine diseases

Epidemiology and semeiotics of endocrine diseases 


The Burden of Hormonal Disorders: A Worldwide Overview With a Particular Look in Italy (adapted from Front Endocrinol 2021)
Andrea Crafa, Aldo E. Calogero1, Rossella Cannarella, Laura M. Mongioì, Rosita A. Condorelli, Emanuela A. Greco, Antonio Aversa and Sandro La Vignera

Endocrine diseases have a considerable impact on public health from an epidemiological point of view and because they may cause long-term disability, alteration of the quality-of-life of the affected patients, and are the fifth leading cause of death. In this extensive review of the literature, we have evaluated the prevalence of the different disorders of endocrine interest in the world and Italy, highlighting their epidemiological, clinical, and economic impact.


Physical examination for endocrinological diseases: does it still play a role? (adapted from J Clin Med 2022)
Andrea Crafa, Rosita A. Condorelli, Rossella Cannarella, Antonio Aversa, Aldo E. Calogero and Sandro La Vignera

A physical examination represents a fundamental step in diagnosing diseases. Due to the role that hormones play in the regulation of numerous biological processes in various organs and systems, endocrine diseases cause a variety of clinical manifestations that can be easily identified with a careful physical examination and can guide the clinician to specific diagnoses. Furthermore, the presence of specific clinical signs in various endocrine‐metabolic diseases can predict the risk of developing comorbidities and serious adverse events. In this article, we present some of the main clinical signs of endocrine‐metabolic diseases and the risk of comorbidities, summarizing the pathogenetic mechanisms that lead to their formation. The aim is to highlight how the identification of these specific signs can reduce the number of dynamic tests and the costs necessary to reach the diagnosis and allow the early identification of any complications associated with these diseases, improving the clinical management of affected patients.


Authors:

Sandro La Vignera, Professor of Endocrinology, University of Catania, Catania, Italy
Antonio Aversa, Professor of Endocrinology, University of Catanzaro, Catanzaro, Italy
Aldo E. Calogero, Professor of Endocrinology, University of Catania, Catania, Italy

Collaborators (alphabetical order):
Rossella Cannarella, Endocrinologist, University of Catania, Catania, Italy
Rosita A. Condorelli, Professor of Endocrinology, University of Catania, Catania, Italy
Andrea Crafa, Graduate School of Endocrinology, University of Catania, Catania, Italy
Emanuela A. Greco, Professor of Endocrinogy, University UNICUSANO, Rome, Italy
Laura M. Mongioì, Endocrinologist, University of Catania, Catania, Italy